O
CRIS icon

OrbiMed’s Curis CRIS Stock Holding History

OrbiMed’s Portfolio CRIS Stock Details CRIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9,087
Closed -$17.3M – 146
2021
Q4 		$17.3M Buy
9,087
+283
+3% +$673K 0.22% 91
2021
Q3 		$27.6M Hold
8,804
– – 0.3% 81
2021
Q2 		$28.4M Sell
8,804
-2,112
-19% -$9.54M 0.29% 83
2021
Q1 		$49.4M Hold
10,916
– – 0.46% 61
2020
Q4 		$35.8M Buy
10,916
+7,812
+252% +$9.38M 0.31% 75
2020
Q3 		$1.45M Hold
3,104
– – 0.02% 138
2020
Q2 		$1.5M Sell
3,104
-292
-9% -$108K 0.02% 130
2020
Q1 		$956K Hold
3,396
– – 0.02% 135
2019
Q4 		$2.31M Buy
3,396
+292
+9% +$212K 0.03% 117
2019
Q3 		$2.78M Buy
+3,104
New +$2.63M 0.05% 105
2015
Q2 		– Sell
-362
Closed -$1.74M – 141
2015
Q1 		$1.74M Sell
362
-613
-63% -$2.96M 0.01% 129
2014
Q4 		$2.92M Hold
975
– – 0.03% 117
2014
Q3 		$2.75M Hold
975
– – 0.03% 119
2014
Q2 		$3.63M Hold
975
– – 0.04% 117
2014
Q1 		$5.5M Hold
975
– – 0.07% 114
2013
Q4 		$5.5M Hold
975
– – 0.08% 95
2013
Q3 		$8.7M Hold
975
– – 0.16% 82
2013
Q2 		$6.22M Buy
+975
New +$6.89M 0.13% 95

Other funds holding CRIS

MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

OrbiMed's CRIS Position: Q1 2022 in Review

OrbiMed sold out of Curis (CRIS) in Q1 2022, closing a stake of 9,087 shares — an estimated $17.3M sold.

OrbiMed first reported a position in CRIS in Q2 2013 and held it in 18 quarters. The position peaked at $49.4M in Q1 2021. 124 funds tracked by Wall St. Rank hold CRIS as of Q1 2022.

  • OrbiMed reported no remaining Curis position as of Q1 2022 after selling out during the quarter.
  • OrbiMed sold 9,087 Curis shares in Q1 2022, an estimated $17.3M.
  • OrbiMed first reported a position in Curis in Q2 2013 and held it in 18 quarters.
  • OrbiMed's Curis position peaked at $49.4M in Q1 2021.
  • 124 funds tracked by Wall St. Rank held Curis as of Q1 2022.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.